Cargando…

Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms

BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liu, Wang, Jiao, Li, Hong-jin, Zhang, Shuo, Jin, Meng-zhu, Chen, Si-ting, Sun, Xiao-ying, Zhou, Ya-qiong, Lu, Yi, Yang, Dan, Luo, Ying, Ru, Yi, Li, Bin, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724303/
https://www.ncbi.nlm.nih.gov/pubmed/34992595
http://dx.doi.org/10.3389/fimmu.2021.759276
_version_ 1784625893607473152
author Liu, Liu
Wang, Jiao
Li, Hong-jin
Zhang, Shuo
Jin, Meng-zhu
Chen, Si-ting
Sun, Xiao-ying
Zhou, Ya-qiong
Lu, Yi
Yang, Dan
Luo, Ying
Ru, Yi
Li, Bin
Li, Xin
author_facet Liu, Liu
Wang, Jiao
Li, Hong-jin
Zhang, Shuo
Jin, Meng-zhu
Chen, Si-ting
Sun, Xiao-ying
Zhou, Ya-qiong
Lu, Yi
Yang, Dan
Luo, Ying
Ru, Yi
Li, Bin
Li, Xin
author_sort Liu, Liu
collection PubMed
description BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoriasis. OBJECTIVE: To assess the efficacy and possible mechanism of S1P and its signal modulators in the treatment of psoriasis-like dermatitis. METHODS: Six databases were searched through May 8, 2021, for studies reporting S1P and its signal modulators. Two reviewers independently extracted information from the enrolled studies. Methodological quality was assessed using SYRCLE’s risk of bias tool. RevMan 5.3 software was used to analyze the data. For clinical studies, the Psoriasis Area and Severity Index score were the main outcomes. For preclinical studies, we clarified the role of S1P and its regulators in psoriasis in terms of phenotype and mechanism. RESULTS: One randomized double-blind placebo-controlled trial and nine animal studies were included in this study. The pooled results showed that compared with control treatment, S1P receptor agonists [mean difference (MD): −6.80; 95% confidence interval (CI): −8.23 to −5.38; p<0.00001], and sphingosine kinase 2 inhibitors (MD: −0.95; 95% CI: −1.26 to −0.65; p<0.00001) alleviated psoriasis-like dermatitis in mice. The mechanism of S1P receptor agonists in treating psoriasis might be related to a decrease in the number of white blood cells, topical lymph node weight, interleukin-23 mRNA levels, and percentage of CD3(+) T cells (p<0.05). Sphingosine kinase 2 inhibitors ameliorated psoriasis in mice, possibly by reducing spleen weight and cell numbers (p<0.05). CONCLUSIONS: S1P receptor agonists and sphingosine kinase 2 inhibitors could be potential methods for treating psoriasis by decreasing immune responses and inflammatory factors.
format Online
Article
Text
id pubmed-8724303
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87243032022-01-05 Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms Liu, Liu Wang, Jiao Li, Hong-jin Zhang, Shuo Jin, Meng-zhu Chen, Si-ting Sun, Xiao-ying Zhou, Ya-qiong Lu, Yi Yang, Dan Luo, Ying Ru, Yi Li, Bin Li, Xin Front Immunol Immunology BACKGROUND: Psoriasis is an autoimmune skin disease associated with lipid metabolism. Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a key role in the development of autoimmune diseases. However, there is currently a lack of comprehensive evidence of the effectiveness of S1P on psoriasis. OBJECTIVE: To assess the efficacy and possible mechanism of S1P and its signal modulators in the treatment of psoriasis-like dermatitis. METHODS: Six databases were searched through May 8, 2021, for studies reporting S1P and its signal modulators. Two reviewers independently extracted information from the enrolled studies. Methodological quality was assessed using SYRCLE’s risk of bias tool. RevMan 5.3 software was used to analyze the data. For clinical studies, the Psoriasis Area and Severity Index score were the main outcomes. For preclinical studies, we clarified the role of S1P and its regulators in psoriasis in terms of phenotype and mechanism. RESULTS: One randomized double-blind placebo-controlled trial and nine animal studies were included in this study. The pooled results showed that compared with control treatment, S1P receptor agonists [mean difference (MD): −6.80; 95% confidence interval (CI): −8.23 to −5.38; p<0.00001], and sphingosine kinase 2 inhibitors (MD: −0.95; 95% CI: −1.26 to −0.65; p<0.00001) alleviated psoriasis-like dermatitis in mice. The mechanism of S1P receptor agonists in treating psoriasis might be related to a decrease in the number of white blood cells, topical lymph node weight, interleukin-23 mRNA levels, and percentage of CD3(+) T cells (p<0.05). Sphingosine kinase 2 inhibitors ameliorated psoriasis in mice, possibly by reducing spleen weight and cell numbers (p<0.05). CONCLUSIONS: S1P receptor agonists and sphingosine kinase 2 inhibitors could be potential methods for treating psoriasis by decreasing immune responses and inflammatory factors. Frontiers Media S.A. 2021-12-21 /pmc/articles/PMC8724303/ /pubmed/34992595 http://dx.doi.org/10.3389/fimmu.2021.759276 Text en Copyright © 2021 Liu, Wang, Li, Zhang, Jin, Chen, Sun, Zhou, Lu, Yang, Luo, Ru, Li and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Liu
Wang, Jiao
Li, Hong-jin
Zhang, Shuo
Jin, Meng-zhu
Chen, Si-ting
Sun, Xiao-ying
Zhou, Ya-qiong
Lu, Yi
Yang, Dan
Luo, Ying
Ru, Yi
Li, Bin
Li, Xin
Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title_full Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title_fullStr Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title_full_unstemmed Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title_short Sphingosine-1-Phosphate and Its Signal Modulators Alleviate Psoriasis-Like Dermatitis: Preclinical and Clinical Evidence and Possible Mechanisms
title_sort sphingosine-1-phosphate and its signal modulators alleviate psoriasis-like dermatitis: preclinical and clinical evidence and possible mechanisms
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724303/
https://www.ncbi.nlm.nih.gov/pubmed/34992595
http://dx.doi.org/10.3389/fimmu.2021.759276
work_keys_str_mv AT liuliu sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT wangjiao sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT lihongjin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT zhangshuo sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT jinmengzhu sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT chensiting sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT sunxiaoying sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT zhouyaqiong sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT luyi sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT yangdan sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT luoying sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT ruyi sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT libin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms
AT lixin sphingosine1phosphateanditssignalmodulatorsalleviatepsoriasislikedermatitispreclinicalandclinicalevidenceandpossiblemechanisms